NCT lookup
Pull any trial record directly from ClinicalTrials.gov.
Sponsor: Hospital do Coracao
Conditions: Metastatic Breast Cancer, Breast Cancer Stage IV
Countries: Brazil
Given the certain benefit in efficacy of adding CDK 4/6 inhibitor to first line endocrine therapy in metastatic breast cancer HR+ HER2- , the aim of this project is to evaluate whether patients without private health insurance may have worse outcomes than privately insured women due to limited access to such class of drugs during their treatments. Prospective observational study with 300 patients divided into two groups, one with patients from the public health system and the second with patients treated in the private service. Patients will be recruited in different regions of Brazil and will be followed for 24 months, stratified according to the use or not of the CDK 4/6 inhibitors.
Sex: ALL
Age: 18 Years to —
Healthy volunteers: No
Study type: OBSERVATIONAL
Inclusion Criteria: * Women may be premenopausal or postmenopausal * Metastatic advanced breast cancer * ER-positive and/or PR-positive, HER2-negative tumor * Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, 2 and 3. * Start of first-line treatment from 2019 Exclusion Criteria: * Localized or locally advanced disease * Lack of information about hormonal receptor and HER2 status * Breast cancer in men * Breast cancer in pregnancy * Have progressed from initiation of first-line treatment to study enrollment
- São Paulo, São Paulo, Brazil